filmov
tv
Prospects for COVID 19 Medicines - Ivor O'Shea (SAI Healthcare Committee).
ะะพะบะฐะทะฐัั ะพะฟะธัะฐะฝะธะต
๐๐๐ฒ๐ป๐ ๐ง๐๐ฝ๐ฒ: Webinar
๐๐ฎ๐๐ฒ: Friday: 1st May, 2020
๐ฆ๐ฝ๐ฒ๐ฎ๐ธ๐ฒ๐ฟ๐/๐ฃ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฒ๐ฟ๐:
๐๐๐๐ ๐๐๐ก๐๐: Ivor OโShea (SAI Healthcare Committee).
๐ถโ๐๐๐: Brendan McCarthy (SAI Healthcare Committee).
๐๐ฒ๐๐ฐ๐ฟ๐ถ๐ฝ๐๐ถ๐ผ๐ป: This online presentation considers the prospects, risks and timelines for vaccines and other medicines to prevent and/or treat COVID-19. In particular, the presentation will cover some aspects that have not, to date, featured prominently in the public debate on this virus. This presentation should be of interest to all actuaries.
๐๐ผ๐ป๐๐ฒ๐ป๐๐: 1. Short biotech primer; 2. Prospects for vaccines; 3. Prospects for antivirals; 4. Prospects for antibodies; 5. Prospects for โrepurposedโ drugs; and 6. Future Scenarios & Conclusion.
๐ฆ๐ฝ๐ฒ๐ฎ๐ธ๐ฒ๐ฟ ๐๐ถ๐ผ๐ด๐ฟ๐ฎ๐ฝ๐ต๐ถ๐ฐ๐ฎ๐น ๐ฑ๐ฒ๐๐ฎ๐ถ๐น๐: Over the past decade, Ivor has invested in over 475 listed biotech companies. Over one third of these biotechs developed medicines for infectious diseases. As a result, Ivor has accumulated practical experience in assessing the prospects and timelines for potential new medicines. Ivor is a member of the Societyโs Healthcare Committee.
๐๐ฎ๐๐ฒ: Friday: 1st May, 2020
๐ฆ๐ฝ๐ฒ๐ฎ๐ธ๐ฒ๐ฟ๐/๐ฃ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ฒ๐ฟ๐:
๐๐๐๐ ๐๐๐ก๐๐: Ivor OโShea (SAI Healthcare Committee).
๐ถโ๐๐๐: Brendan McCarthy (SAI Healthcare Committee).
๐๐ฒ๐๐ฐ๐ฟ๐ถ๐ฝ๐๐ถ๐ผ๐ป: This online presentation considers the prospects, risks and timelines for vaccines and other medicines to prevent and/or treat COVID-19. In particular, the presentation will cover some aspects that have not, to date, featured prominently in the public debate on this virus. This presentation should be of interest to all actuaries.
๐๐ผ๐ป๐๐ฒ๐ป๐๐: 1. Short biotech primer; 2. Prospects for vaccines; 3. Prospects for antivirals; 4. Prospects for antibodies; 5. Prospects for โrepurposedโ drugs; and 6. Future Scenarios & Conclusion.
๐ฆ๐ฝ๐ฒ๐ฎ๐ธ๐ฒ๐ฟ ๐๐ถ๐ผ๐ด๐ฟ๐ฎ๐ฝ๐ต๐ถ๐ฐ๐ฎ๐น ๐ฑ๐ฒ๐๐ฎ๐ถ๐น๐: Over the past decade, Ivor has invested in over 475 listed biotech companies. Over one third of these biotechs developed medicines for infectious diseases. As a result, Ivor has accumulated practical experience in assessing the prospects and timelines for potential new medicines. Ivor is a member of the Societyโs Healthcare Committee.